Valproic acid for agitation in the intensive care unit : an observational study of psychiatric consults
© 2023. Crown..
BACKGROUND: Agitation is a common clinical problem encountered in the intensive care unit (ICU). Treatment options are based on clinical experience and sparse quality literature.
AIM: The aim of this study was to describe the effect of valproic acid (VPA) as adjuvant treatment for agitation in the ICU, identify predictors of response to VPA and evaluate the independent effect of VPA on agitation compared to standard of care (SOC).
METHOD: This retrospective single center observational study evaluated adult patients admitted to the ICU for whom a psychiatric consultation was requested for agitation management, with agitation defined as a Richmond Agitation Sedation Score of 2 or greater. A descriptive analysis of the proportion of agitation-free patients per day of follow-up, the incidence of agitation-related-events, as well as the evolution of co-medications use over time are presented. A logistic regression model was used to assess predictors of VPA response, defined as being agitation-free on Day 7 and generalized estimating equations were used to evaluate the independent effect of VPA as adjuvant therapy for agitation in the critically ill.
RESULTS: One hundred seventy-five patients were included in the study with 78 receiving VPA. The percentage of agitation-free patients on VPA was 6.5% (5/77) on Day 1, 14.1% (11/78) on Day 3 and 39.5% (30/76) on Day 7. Multivariate regression model for clinical and demographic variables identified female gender as predictor of response on Day 7 (OR 6.10 [1.18-31.64], p = 0.03). The independent effect of VPA was non-significant when compared to SOC.
CONCLUSION: Although VPA used as adjuvant treatment was associated with a decrease in agitation, its effect when compared to SOC did not yield significant results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
International journal of clinical pharmacy - 46(2024), 1 vom: 16. Feb., Seite 177-185 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
White, Geneviève [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
614OI1Z5WI |
|---|
| Anmerkungen: |
Date Completed 01.02.2024 Date Revised 01.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11096-023-01661-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365625043 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365625043 | ||
| 003 | DE-627 | ||
| 005 | 20240201232040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11096-023-01661-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1277.xml |
| 035 | |a (DE-627)NLM365625043 | ||
| 035 | |a (NLM)38071694 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a White, Geneviève |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Valproic acid for agitation in the intensive care unit |b an observational study of psychiatric consults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2024 | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Crown. | ||
| 520 | |a BACKGROUND: Agitation is a common clinical problem encountered in the intensive care unit (ICU). Treatment options are based on clinical experience and sparse quality literature | ||
| 520 | |a AIM: The aim of this study was to describe the effect of valproic acid (VPA) as adjuvant treatment for agitation in the ICU, identify predictors of response to VPA and evaluate the independent effect of VPA on agitation compared to standard of care (SOC) | ||
| 520 | |a METHOD: This retrospective single center observational study evaluated adult patients admitted to the ICU for whom a psychiatric consultation was requested for agitation management, with agitation defined as a Richmond Agitation Sedation Score of 2 or greater. A descriptive analysis of the proportion of agitation-free patients per day of follow-up, the incidence of agitation-related-events, as well as the evolution of co-medications use over time are presented. A logistic regression model was used to assess predictors of VPA response, defined as being agitation-free on Day 7 and generalized estimating equations were used to evaluate the independent effect of VPA as adjuvant therapy for agitation in the critically ill | ||
| 520 | |a RESULTS: One hundred seventy-five patients were included in the study with 78 receiving VPA. The percentage of agitation-free patients on VPA was 6.5% (5/77) on Day 1, 14.1% (11/78) on Day 3 and 39.5% (30/76) on Day 7. Multivariate regression model for clinical and demographic variables identified female gender as predictor of response on Day 7 (OR 6.10 [1.18-31.64], p = 0.03). The independent effect of VPA was non-significant when compared to SOC | ||
| 520 | |a CONCLUSION: Although VPA used as adjuvant treatment was associated with a decrease in agitation, its effect when compared to SOC did not yield significant results | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Agitation | |
| 650 | 4 | |a Critical care | |
| 650 | 4 | |a Intensive care | |
| 650 | 4 | |a Psychiatry | |
| 650 | 4 | |a Valproate | |
| 650 | 4 | |a Valproic acid | |
| 650 | 7 | |a Valproic Acid |2 NLM | |
| 650 | 7 | |a 614OI1Z5WI |2 NLM | |
| 700 | 1 | |a Adessky, Noah |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Fei-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Regazzoni, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Tourian, Leon |e verfasserin |4 aut | |
| 700 | 1 | |a Chagnon, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Gursahaney, Ashvini |e verfasserin |4 aut | |
| 700 | 1 | |a Alharbi, Majed |e verfasserin |4 aut | |
| 700 | 1 | |a Williamson, David |e verfasserin |4 aut | |
| 700 | 1 | |a Perreault, Marc M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical pharmacy |d 2011 |g 46(2024), 1 vom: 16. Feb., Seite 177-185 |w (DE-627)NLM203361717 |x 2210-7711 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2024 |g number:1 |g day:16 |g month:02 |g pages:177-185 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11096-023-01661-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2024 |e 1 |b 16 |c 02 |h 177-185 | ||